MusclePharm Corporation (OTC: MSLP), a developer, manufacturer and marketer of nutritional supplements for athletes, recently reported its preliminary 2012 first-quarter financial results.
MSLP’s net sales for the first quarter ended March 31, 2012 were approximately $19 million, up from $4 million reported in the first quarter of 2011. The year-over-year increase in net sales was driven by 400% growth in International sales.
Income from operations for the first quarter came in at approximately $1 million, compared with loss from operations of $1 million reported for the same period in the previous year.
MSLP CEO Brad Pyatt said that at the end of the first quarter, the company had a sales backlog of $4.3 million, which was shipped during the second quarter.
Last week, MusclePharm announced that due to the FDA ban on substance DMAA, it expects to capture a wider market share. DMAA, which is used by many supplement companies in their products, is not used by MSLP in any of its products. The substance has been banned by the FDA due to potentially fatal side effects.
Recent Comments